FDA HCT/P Enforcement Overview | 21 CFR Part 1271 Compliance and Regulatory Oversight

FDA Enforcement Overview for HCT/P Regulation

The U.S. Food and Drug Administration regulates human cell and tissue products through the regulatory framework defined in 21 CFR Part 1271. Oversight includes inspection programs, compliance monitoring, and enforcement actions when activities fall outside the regulatory criteria governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).

Understanding the history of enforcement activity provides context for how the agency interprets and applies regulatory requirements associated with tissue-based products.

Additional regulatory structure is explained in the overview of 21 CFR Part 1271 regulatory framework and the comparison between Section 361 and Section 351 regulatory classification pathways.

FDA regulatory enforcement framework for HCT/Ps illustrating compliance oversight under 21 CFR Part 1271 including warning letters FDA Form 483 inspection observations import alerts and regulatory classification review
Educational overview of FDA compliance oversight and enforcement mechanisms applicable to Human Cells, Tissues, and Cellular and Tissue-Based Products regulated under 21 CFR Part 1271.

Regulatory Authority

The FDA derives regulatory authority for tissue products through statutory provisions including the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act.

Products that meet all criteria outlined in 21 CFR 1271.10(a) may be regulated solely under Section 361 of the Public Health Service Act. Products that do not meet these criteria may require regulation under the biologics licensing pathway associated with Section 351.

Types of Regulatory Actions

  • Warning letters
  • Untitled letters
  • Inspection observations (FDA Form 483)
  • Import alerts
  • Product seizures or injunctions

These actions may arise during inspection of tissue establishments or through review of marketing practices that may influence regulatory classification.

Common Compliance Considerations

Role of FDA Guidance and Policy Development

The FDA periodically publishes guidance documents to clarify regulatory expectations and to explain how existing regulations may be interpreted in evolving areas of tissue-based medical technology.

These guidance documents help provide transparency regarding how regulatory criteria such as minimal manipulation and homologous use may be applied during compliance review.

Educational Purpose of This Resource

This page provides educational information regarding the regulatory framework and enforcement environment associated with human cell and tissue products regulated under 21 CFR Part 1271.

Additional regulatory education materials are available within the Regulatory Resource Library.

This information is provided for educational purposes only. Certain referenced materials may be regulated as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271. Registration under 21 CFR Part 1271 does not constitute FDA approval, clearance, endorsement, or evaluation of safety or effectiveness. This information is not intended to diagnose, treat, cure, or prevent any disease.